Retatrutide: what the research actually says

Retatrutide gets discussed alongside approved drugs like Ozempic and Zepbound, and that's understandable — it comes from the same class of research and the same company (Eli Lilly). But it belongs in a different category: it is still an experimental compound moving through the FDA's clinical trial and review process, not a drug you can be legally prescribed today. For how it fits into the broader weight-loss peptide landscape, see our peptides for weight loss overview, and for an explanation of what these hormone-receptor drugs actually are, start with what are peptides.

What retatrutide is

Retatrutide (Lilly's internal code LY3437943) is a "triple agonist": a single molecule engineered to activate three separate hormone receptors — GIP, GLP-1, and glucagon — at once. That's one receptor more than tirzepatide (Zepbound/Mounjaro, a dual GIP/GLP-1 agonist) and two more than semaglutide (Ozempic/Wegovy, GLP-1 only). The added glucagon-receptor activity is the mechanistic reason researchers are watching it closely. Glucagon promotes energy expenditure and fat burning in ways that GLP-1 alone doesn't fully replicate, which may explain why retatrutide's early efficacy numbers exceed those of approved drugs in head-to-head trial comparisons.

Like other drugs in this class, retatrutide is administered by once-weekly subcutaneous injection with a gradual dose-escalation schedule — patients start at 2 mg and step up over several weeks to reach their target dose of 4 mg, 9 mg, or 12 mg. The step-wise escalation is designed to reduce gastrointestinal side effects that come on quickly with a full dose. Retatrutide is an investigational molecule and, as of 2026, is legally available only to participants in Lilly's clinical trials.

Phase 2 evidence: where the story started

The key early published data is a randomized, placebo-controlled Phase 2 trial in the New England Journal of Medicine, led by Yale's Dr. Ania Jastreboff and colleagues.¹ In 338 adults with obesity, the highest studied dose (12 mg weekly) produced a 24.2% average reduction in body weight at 48 weeks, compared with 2.1% for placebo. At that dose, 83% of participants lost 15% or more of their body weight. The most common side effects were gastrointestinal (nausea and related symptoms), generally mild to moderate and dose-related, alongside a dose-dependent rise in heart rate that peaked around 24 weeks and declined afterward.

Phase 3 TRIUMPH-1: the pivotal obesity trial

In May 2026, Eli Lilly released top-line results from TRIUMPH-1 (NCT05929066), the pivotal Phase 3 obesity trial registered on ClinicalTrials.gov. This was a substantially larger study: 2,339 participants, 80 weeks, randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo.

At 80 weeks, participants on the highest dose lost an average of 28.3% of their body weight (about 70.3 lbs), compared with 3.9% for placebo. At the 4 mg dose — reached via just one escalation step — participants still lost an average of 19.0% (47.2 lbs). In a pre-specified extension of up to 104 weeks for participants with a baseline BMI ≥35, those who continued on 12 mg lost an average of 30.3% of their body weight, or approximately 85 lbs. 45.3% of participants in the 12 mg arm achieved weight loss of 30% or more — a threshold long associated with bariatric surgery outcomes.

Those results are striking in context. The two currently approved GLP-1-class drugs for obesity showed smaller average weight losses in their own Phase 3 trials: semaglutide (Wegovy) produced roughly 14.9% at 68 weeks in STEP-1, and tirzepatide (Zepbound) produced roughly 20.9% at 72 weeks in SURMOUNT-1. Retatrutide's Phase 3 numbers are not from a head-to-head comparison with those drugs — they're from different trials, with different populations and different follow-up periods — so the comparison has limits. But the magnitude is the reason this compound is getting serious attention.

Evidence-grade table: retatrutide trial data at a glance

All results are from the efficacy estimand (had all participants remained on study drug). RCT = randomized controlled trial. Phase 3 is the regulatory standard before FDA approval. Lower weight loss in the T2D trial reflects the shorter duration and a population with type 2 diabetes, which is typically harder to treat for weight loss.

The type 2 diabetes Phase 3 trial

Separately from the obesity program, Lilly is also developing retatrutide for type 2 diabetes. The first Phase 3 diabetes trial — TRANSCEND-T2D-1 (NCT06354660) — enrolled 537 adults with type 2 diabetes not adequately controlled by diet and exercise, and was published in The Lancet in June 2026.² At 40 weeks, participants on the 12 mg dose achieved a mean HbA1c reduction of 1.94 percentage points compared with 0.81 for placebo — a clinically significant difference. Body weight fell by an average of 15.3% on 12 mg versus 2.6% for placebo. The trial paper describes retatrutide as still "under clinical development," and 94% of participants completed the study on drug, suggesting reasonable tolerability in a diabetes population.

What broader research is still underway

Weight loss and glycemic control are not the only things Lilly is studying. The Phase 3 program for retatrutide spans multiple indications and is among the broadest single-drug trial programs in recent memory:

• TRIUMPH-2 — retatrutide in adults with obesity or overweight and type 2 diabetes
• TRIUMPH-3 — retatrutide in adults with obesity or overweight and established cardiovascular disease
• Basket trials embedded in TRIUMPH-1 for knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea
• Separate studies in chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)

The TRIUMPH Phase 3 clinical development program has enrolled more than 5,800 participants across its initial registrational trials. Results from several of these arms remain pending as of mid-2026. The FDA does not require cardiovascular outcome trial results before approving a diabetes or obesity drug, but Lilly's decision on when to file an NDA (New Drug Application) may be shaped by how much of this data it wants to include.

Where retatrutide stands in 2026

Retatrutide has moved into Phase 3, the stage required before an FDA approval decision, and pivotal obesity data has been publicly released. However, as of August 2026, no NDA has been submitted to the FDA, and openFDA's public drug-approval database shows no approved application for retatrutide. Additional Phase 3 results are expected later in 2026. Lilly has not publicly announced a specific submission timeline, though industry analysts broadly expect an NDA filing for the obesity indication in late 2026 or early 2027, with potential approval following 12 months or more after submission if accepted for review.

"The interesting thing about GLP-1s is that even with all the research we already have, we're continuing to find even more benefits and risks related to GLP-1s, which may be why there's so much interest in these newer peptides. They hint at promising possibilities."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, in the American Medical Association (April 2026)

Side effects and known risks

Across both Phase 2 and Phase 3 trials, retatrutide's side effect profile was broadly similar to other GLP-1-class drugs: mostly gastrointestinal, mostly mild to moderate, and mostly concentrated during the dose-escalation period. In TRIUMPH-1, the most commonly reported events in the 12 mg group were nausea (42.4% vs. 14.8% placebo), diarrhea (32.0% vs. 13.5%), constipation (26.1% vs. 10.9%), and vomiting (25.3% vs. 4.8%).

One side effect that appears more distinctive to retatrutide than to semaglutide or tirzepatide is dysesthesia — tingling, burning, or altered skin sensations. In TRIUMPH-1, dysesthesia occurred in 5.1% to 12.5% of participants receiving retatrutide (across doses) versus just 0.9% in the placebo group. Most events were mild and the majority resolved during treatment. The cause is not fully understood; one hypothesis is that the glucagon receptor activity (absent in the other approved drugs) may be relevant.

There was also a dose-dependent rise in resting heart rate in the Phase 2 trial — a signal observed with other GLP-1-based drugs — that peaked around 24 weeks and trended back toward baseline. Discontinuation rates due to adverse events in TRIUMPH-1 ranged from 4.1% (4 mg) to 11.3% (12 mg), compared with 4.9% for placebo. No severe hypoglycemia was reported in the diabetes Phase 3 trial (TRANSCEND-T2D-1) in any arm. As with all investigational drugs, the full safety picture will not be known until the drug has been prescribed to a much larger and more diverse population outside of trial conditions.

How retatrutide compares to approved alternatives

The comparison that matters most from a patient perspective isn't mechanism-on-paper but rather regulatory status. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are FDA-approved drugs that can be legally prescribed today. Retatrutide cannot be. That gap matters enormously for anyone deciding whether to wait for retatrutide versus starting with an approved drug now — because "approved" means the drug has completed the full FDA review of its safety and efficacy data, there is a regulated manufacturing process, there is a prescribing label, and physicians can legally write a prescription. None of those protections exist for retatrutide in 2026.

From a mechanism standpoint, the extra glucagon-receptor activity is the key differentiator. In preclinical and clinical data, glucagon receptor activation appears to increase energy expenditure and act on fat stores differently than GLP-1 alone, which may be why the weight loss numbers in retatrutide trials consistently exceed those of dual or single agonists. Whether that translates to better long-term cardiovascular outcomes — the metric that matters most for regulators and physicians over a multi-decade obesity treatment course — remains to be seen in the ongoing TRIUMPH-3 trial. For a fuller explanation of what's currently approved and how approval status shapes what's actually available, see are peptides legal.

Why "not approved yet" still matters

Because retatrutide has not been approved, there is no legal, regulated product you can be prescribed today. Anything marketed online as "retatrutide" outside of a clinical trial is not manufactured under FDA drug oversight, has no verified purity or dosing, and carries the same buyer-beware profile as any other unapproved injectable peptide — regardless of how strong the underlying Phase 2 and Phase 3 science looks. Strong trial data and an approved, prescribable product are two different things until the FDA review is actually complete. The FDA does not simply approve a drug because its trial data looks good; it reviews the complete manufacturing process, the risk management plan, and the full safety database before making any decision. That process takes time even after an NDA is filed.

It is also worth noting that promising Phase 3 data has not historically guaranteed approval on the first attempt. The FDA has asked for additional data, required label changes, or delayed approval for drugs with strong trial results before. Retatrutide's Phase 3 obesity numbers are genuinely impressive, but they do not mean FDA approval is automatic or imminent.

What to do if you're interested

If you want access to a GIP/GLP-1/glucagon-class medication today, the honest options are the ones with completed FDA approval, discussed with a licensed physician who can evaluate whether you're a candidate. Tirzepatide (Zepbound) is the closest approved drug mechanically — a dual GIP/GLP-1 agonist from the same company — and has Phase 3 data showing meaningful weight loss. For retatrutide specifically, the responsible path is watching for an NDA filing and subsequent FDA decision, or asking a physician about enrolling in one of the active clinical trials registered on ClinicalTrials.gov. Sourcing an unregulated version from a compounding pharmacy or online peptide vendor does not give you access to the drug that produced those trial results. See how to try peptides safely for a broader framework on navigating this space without putting yourself at risk.